iCAD is releasing new clinical data on an approach known as intraoperative radiation therapy (IORT), using the company’s Xoft Axxent Electronic Brachytherapy (eBx) System, to treat patients with early stage breast cancer and nonmelanoma skin cancer. The data is being presented at the American Society for Radiation Oncology (ASTRO) meeting, now taking place in Boston.
iCAD is also showcasing its newest electronic brachytherapy technology at its booth (#4087) at the meeting, which runs through Wednesday, Sept. 28.
Brachytherapy is an advanced cancer treatment that relies on the placement of radioactive seeds or sources near a tumor site, giving a high radiation dose to the tumor while reducing exposure to healthy tissues.
In the Xoft system, a miniaturized high dose rate X-ray source is used to apply radiation directly to the cancerous tumor bed. Unlike traditional high-dose rate brachytherapy technologies, this form of brachytherapy does not require radioactive isotopes, heavy shielding, or major capital equipment, so as to reduce treatment costs, improve convenience, and have fewer side effects.
“The Xoft System offers our customers the versatility to treat multiple cancer types in one integrated system. Our advanced platform technology streamlines the delivery of care, increasing patient satisfaction and positioning the facility as a leader in patient-centric, value-based medicine,” said Ken Ferry, CEO of iCAD in a press release.
Posters presented at the ASTRO meeting include:
- Alam M. Nisar Syed, MD, demonstrating in poster (#2134) the safety of IORT with the Xoft System, as well as its low morbidity and good-to-excellent breast preservation results, drawn from clinical data involving the system’s use in 827 patients with early stage breast cancer at 27 hospitals.
- Ajay Bhatnagar, MD, MBA, presenting in the poster (#3750) the results of a survey given to nonmelanoma skin cancer patients 32 to 72 months post-treatment with Xoft eBx. Results found that demonstrating that 96 percent were satisfied with their clinical and cosmetic treatment outcomes. Dr. Bhatnagar is also presenting updated data on the treatment of 282 lesions in 187 of these skin cancer patients, showing that at up to five years post-treatment, nearly all had good-to-excellent physical appearance (cosmesis), with only three recurrences.
“A growing body of research continues to highlight the Xoft System’s clinical success and drive interest in adopting electronic brachytherapy from customer sites around the world. We are particularly encouraged by customer engagement and increased traction for the skin eBx application, which is further supported by positive clinical data,” Ferry said.